|
Oct 8
|
Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC
|
|
Jun 24
|
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares
|
|
Jun 21
|
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
|
|
Jun 18
|
Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR
|
|
Jun 18
|
Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including Encouraging Data from US Study in CML and Ph+ ALL
|
|
May 16
|
EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress
|
|
Jan 17
|
Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)
|
|
Jan 11
|
Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference
|
|
Jan 2
|
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference
|
|
Aug 7
|
Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with CLL/SLL
|